

# PRESS RELEASE



**HANSA**  
BIOPHARMA

## Increase of number of shares and votes in Hansa Biopharma AB

Lund, Sweden September 30, 2019. Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that the Company's registered share capital and number of outstanding shares and votes have increased during the month of September 2019.

As previously announced on 2 September 2019, Hansa Biopharma's board of directors resolved to issue 715,910 class C shares, by virtue of the authorization by the general meeting held on 22 May 2019 as part of the implementation of the incentive programme LTIP 2019, which was adopted by the annual general meeting held on 22 May 2019. All class C shares are owned by the Company.

As of today, the total number of registered and outstanding shares of Hansa Biopharma amounts to 41,447,564, whereof 40,026,107 are ordinary shares and 1,421,457 are class C shares. As of today, the number of votes in Hansa Biopharma amounts to 40,168,252.7, and the registered share capital amounts to SEK 41,447,564.

This is information that Hansa Biopharma AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act

The information was submitted for publication, through the contact person set out below at 08:00 (CET) on September 30, 2019.

### Contact information

Klaus Sindahl  
Head of Investor Relations  
Hansa Biopharma  
M: +46 (0) 709-298 269  
E: klaus.sindahl@hansabiopharma.com

Rolf Gulliksen  
Head of Corporate Communications  
Hansa Biopharma  
M: +46 (0) 733-328 634  
E: rolf.gulliksen@hansabiopharma.com

### About Hansa Biopharma

Hansa Biopharma is leveraging its proprietary immunomodulatory enzyme technology platform to develop treatments for rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection and cancer.

The Company's lead product, imlifidase, is a unique antibody-degrading enzyme to enable kidney transplantation in highly sensitized patients with potential for further development in other solid organ transplantation and acute autoimmune indications. Imlifidase is currently under potential marketing authorization by EMA. Hansa's research and development program is advancing the next generation of the Company's technology to develop novel IgG-cleaving enzymes with lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology.

Hansa Biopharma is based in Lund, Sweden and also has operations in the UK and US.

Hansa Biopharma  
Scheelevägen 22  
SE- 223 63 Lund, Sweden  
Phone: +46 46 16 56 70  
[www.hansabiopharma.com](http://www.hansabiopharma.com)

Nasdaq OMX Stockholm  
Ticker: HNSA  
ISIN: SE 0002148817